Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Capital Expenditures (2016 - 2025)

Amicus Therapeutics' Capital Expenditures history spans 16 years, with the latest figure at -$2.9 million for Q4 2025.

  • For the quarter ending Q4 2025, Capital Expenditures fell 1115.28% year-over-year to -$2.9 million, compared with a TTM value of $73000.0 through Dec 2025, down 97.95%, and an annual FY2025 reading of $73000.0, down 97.95% over the prior year.
  • Capital Expenditures for Q4 2025 was -$2.9 million at Amicus Therapeutics, down from $2.8 million in the prior quarter.
  • The five-year high for Capital Expenditures was $5.4 million in Q3 2023, with the low at -$4.8 million in Q4 2023.
  • Average Capital Expenditures over 5 years is $485400.0, with a median of $250000.0 recorded in 2024.
  • Biggest YoY gain for Capital Expenditures was 2597.22% in 2023; the steepest drop was 8557.89% in 2023.
  • Tracing FOLD's Capital Expenditures over 5 years: stood at -$676000.0 in 2021, then soared by 496.01% to $2.7 million in 2022, then tumbled by 280.84% to -$4.8 million in 2023, then surged by 105.95% to $288000.0 in 2024, then crashed by 1115.28% to -$2.9 million in 2025.
  • Per Business Quant, the three most recent readings for FOLD's Capital Expenditures are -$2.9 million (Q4 2025), $2.8 million (Q3 2025), and -$38000.0 (Q2 2025).